Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant ...
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months ...
After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...
The Taylor City Council has approved a development agreement that could pave the way for a 664-acre data center campus just ...
As a company takes steps to transform the former Homer City Generating Station into what would be the largest natural ...
Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occ ...
(n=6) remain disease-free more than two years after treatment; 80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at ...
Utility regulators will consider whether to approve a third private methane gas power plant specifically for data center use in Nevada as NV Energy struggles to keep up with a surge of new demand.
Linn County wants Google to help pay for an independent, county-controlled study of local water resources before the company ...
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, ...
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies ...
For patients with desmoid tumors, treatment goals extend beyond tumor shrinkage to include symptom relief and improved physical function,” said Bob Lechleider, M.D., Chief Medical Officer of Immunome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results